InvestorsHub Logo
Followers 38
Posts 3367
Boards Moderated 0
Alias Born 11/27/2014

Re: None

Wednesday, 04/24/2019 8:55:02 AM

Wednesday, April 24, 2019 8:55:02 AM

Post# of 48
Didn’t see this posted here, so thought I would.

Beleave Announces Initial Cannabis Oil Sales After Receiving Health Canada Authorization Derivatives with Higher-Margins Increasing Growth and Revenues

Toronto, Ontario— April 8, 2019 – Beleave Inc. (CSE: BE) (OTCQX: BLEVF) ("Beleave" or the "Company") is pleased to announce that its wholly-owned subsidiary Beleave Kannabis Corp has commenced sales of cannabis oil products at its licensed facility in Hamilton, Ontario.
Beleave has completed its first wholesale transfer of two bulk lots of cannabis oil to another standard processor license holder, as well as having begun cannabis oil product sales to medicinal patients through its online store https://shop.beleave.com. The Company received authorization from Health Canada to sell cannabis oil products in January 2019.
“We've been looking forward to sharing these efforts with our patients and the entire Beleave community. I'm happy to say that the time has finally come,” said Roger Ferreira, Chief Science Officer at Beleave. “Our whole team has been working hard to ensure we're delivering on our commitment to produce high-quality products that we can all be proud of. We continue to invest in our research and development pipeline in anticipation of future opportunities in the Canadian cannabis derivatives market.”
Current product offerings available to medicinal patients include a blended and balanced THC/CBD cannabis oil. These high-quality and pure cannabis oil products are being offered to patients in convenient and easy-to-use 30 mL bottles with an applicator – allowing for precise dosing control by the patient. MCT, a non-allergenic, flavourless and odourless oil widely-used for pharmaceutical applications, will be used as the carrier oil for Beleave's cannabis oil products to assist in the timely delivery and absorption of THC and CBD.
Cannabis oil production is already underway at Beleave's industrial extraction laboratory using proprietary (patent-pending) methods. This process involves the activation, extraction and purification of THC and CBD using only potable components, without using any organic solvents. In addition to producing oils for Beleave's own medicinal patients, the Company is actively engaged in contract negotiations to offer the same extraction, processing, packaging and distribution services to other micro and standard processor licensed companies.
“We are very excited and proud of our scientific research team and the quality of the work they're producing,” said Bill Panagiotakopoulos, Chief Executive Officer at Beleave. “In conjunction with our dried flower products, we feel our company's success will also rely on the production and processing of oils and derivatives for the adult recreational market, antici- pated for later this year. This is another great milestone for Beleave.”
Patent applications submitted for the Company's processes include a regularly submitted United States patent application (U.S. Patent Application 16/201,547), as well as a Patent Cooperation Treaty (PCT) and International Application (PCT Patent Application PCT/- CA2018/051508).
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BE News